AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback